The Pharma Data

OCTOBER 18, 2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.

Vaccine 40

Vaccine Immune Response Virus Hospitals 40

Drug Target Review

OCTOBER 4, 2023

10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

NIH Director's Blog: Drug Development

MAY 21, 2020

This structural information helps to clarify the precise biochemistry of the complex interaction between SARS-CoV-2 and the antibody, providing a much-needed guide for the rational design of targeted drugs and vaccines. In the U.S. Stay tuned for more information about these potentially significant advances in the next few months.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. These days, the Veesler lab has been hard at work to understand SARS-CoV-2 and the human immune response to the virus.

Virus 52

Virus Immune Response Clinical Trials Treatment 52

Codon

AUGUST 27, 2024

For example, many different filoviruses attack white blood cells and cause similar innate immune responses , which makes it difficult to identify a particular species from only their DNA. In 2003, the DHS launched the BioWatch program after five people died and twenty fell ill from touching envelopes laced with anthrax spores.

DNA 81

DNA Laboratories Hospitals Virus 81